FDA Office of Prescription Drug Promotion (OPDP) · United States

FDA OPDP Off-Label Promotion Prohibition

Drug firms may not promote prescription drugs for unapproved uses; scientific information on unapproved uses may go to HCPs only if separate from promotion and accompanied by the disclosures in FDA's 2025 guidance.

21 U.S.C. 352(a), (f), (n); 21 CFR 202.1(e)(4)(i)(a), (e)(6)(i), (e)(6)(xi); 21 CFR 201.128; FDA SIUU Q&A Guidance (Jan. 2025) sec. V, Q2-Q5

What is FDA OPDP Off-Label Promotion Prohibition?

Drug firms may not promote prescription drugs for unapproved uses; scientific information on unapproved uses may go to HCPs only if separate from promotion and accompanied by the disclosures in FDA's 2025 guidance. Apply to consumer and HCP-directed prescription drug promotion and scientific communications in any US channel.

US Federal

Read official source

Last reviewed: 2026-11-05

General information, not legal advice.

Who does this rule apply to?

general_audience, general_adults_18plus, customers, patients, health_professionals · Prescription Drug · pharma

Where does this rule apply?

United States

Which marketing channels are covered?

all_channels

When does this rule take effect?

2018-06-04

What does this rule require?

Drug firms may not promote prescription drugs for unapproved uses; scientific information on unapproved uses may go to HCPs only if separate from promotion and accompanied by the disclosures in FDA's 2025 guidance.

How can marketing teams comply?

Apply to consumer and HCP-directed prescription drug promotion and scientific communications in any US channel.

Where can I read the official source?

Read official source

Key facts

Regulatory authority
FDA Office of Prescription Drug Promotion (OPDP)
Jurisdiction
United States
Official citation
21 U.S.C. 352(a), (f), (n); 21 CFR 202.1(e)(4)(i)(a), (e)(6)(i), (e)(6)(xi); 21 CFR 201.128; FDA SIUU Q&A Guidance (Jan. 2025) sec. V, Q2-Q5
Published
2026-11-16
Effective date
2018-06-04
Channel
all_channels
Products
Prescription Drug
Audiences
general_audience, general_adults_18plus, customers, patients, health_professionals

Frequently asked questions

What is FDA OPDP Off-Label Promotion Prohibition?

Drug firms may not promote prescription drugs for unapproved uses; scientific information on unapproved uses may go to HCPs only if separate from promotion and accompanied by the disclosures in FDA's 2025 guidance.

Who does this rule apply to?

general_audience, general_adults_18plus, customers, patients, health_professionals · Prescription Drug · pharma

Where does this rule apply?

United States

Which marketing channels are covered?

all_channels

When does this rule take effect?

2018-06-04

Request a free compliance scan of your homepage and book a time with Warrant.

Get a free homepage compliance scan